Peripheral neuropathy and nerve damage involve axonal degeneration, impaired myelin maintenance, reduced nerve growth factor signaling, and oxidative stress in neuronal mitochondria. Recovery requires neurotrophic support, axonal regeneration promotion, anti-inflammatory intervention, and mitochondrial protection. Peptide research offers targeted tools for each of these requirements.
1. BPC-157 — Peripheral Nerve Regeneration
BPC-157 has demonstrated remarkable nerve regeneration capacity in animal models — promoting axonal regrowth, remyelination, and functional recovery after peripheral nerve crush and transection injuries. It upregulates VEGF in neural tissue (promoting vascular supply to nerves), modulates nerve growth factor receptor expression, and reduces the neuroinflammation that impairs regeneration.
Dosing Protocol: 250–500 mcg SubQ daily, ideally near the affected nerve region. Cycle: 8–12 weeks; severe neuropathy may require 16 weeks.
2. Semax — BDNF / NGF Upregulation
Semax upregulates BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) — the two primary neurotrophic signals required for neuronal survival and axonal regeneration. In peripheral neuropathy, declining neurotrophic support accelerates degeneration; Semax restores the neuronal survival signals needed for both central and peripheral nerve maintenance.
Dosing Protocol: 300–600 mcg intranasal daily. SubQ: 300–500 mcg daily. Best used continuously during nerve repair protocols.
3. ARA-290 — Neuroprotection / Pain Reduction
ARA-290 is a non-hematopoietic erythropoietin analog that specifically activates the tissue-protective EPO receptor complex on peripheral nerves. It has demonstrated significant reduction of neuropathic pain, improvement in small fiber nerve density, and neuroprotective effects in diabetic neuropathy — with published clinical trial data supporting its use.
Dosing Protocol: 4–8 mg SubQ daily for 28-day courses based on clinical trial protocols. Cycle: 28 days on, 28 days off.
4. SS-31 — Neuronal Mitochondrial Protection
Mitochondrial dysfunction is a primary driver of axonal degeneration in both diabetic and chemotherapy-induced neuropathy. SS-31 protects neuronal mitochondrial membranes from oxidative damage, restores ATP production in axons, and reduces the mitochondrial ROS that drives progressive nerve fiber loss.
Dosing Protocol: 1–3 mg SubQ daily. Cycle: 4–8 weeks.
BPC-157 drives the axonal regeneration needed for structural nerve recovery. Semax ensures the BDNF and NGF neurotrophic environment that sustains regenerating neurons. ARA-290 provides targeted EPO receptor-mediated neuroprotection with published clinical evidence for peripheral neuropathy. SS-31 eliminates the mitochondrial oxidative damage that causes progressive axonal degeneration.
- Seiwerth S et al. (2018). BPC-157 nerve regeneration. Peptides.
- Eremin KO et al. (2012). Semax NGF/BDNF effects. Biochemistry (Moscow).
- Heij L et al. (2013). ARA-290 and neuropathic pain. PLoS ONE. DOI: 10.1371/journal.pone.0062286
- Szeto HH et al. (2014). SS-31 neuronal mitochondria. J Mol Cell Cardiol.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).